N/A N=230 Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)
Non Small-cell Lung Cancer
Primary: FISH, IHC, RT-qPCR Comparison — 18; 15; 5; 182 participants — p=< 0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=161 Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Non-Small-Cell Lung Carcinoma
Primary: Number of Participants Classified According to Treatments Received for Anaplastic Lymphoma Kinase Positive-non-Small Cell Lung Cancer (ALK + NSCLC) in Sequence — 103; 8…
Phase 2 N=6 AUY922 for Advanced ALK-positive NSCLC
Non Small Cell Lung Cancer
Primary: Objective Response Rate — 0 Participants
Phase 3 N=347 An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Progression-Free Survival (PFS) — 7.7; 3.0 months — p=<0.0001
Phase 2 N=1,066 An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate — 54.1; 40.5 Percentage of participants
Phase 3 N=275 ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
Non-small Cell Lung Cancer · Lung Cancer · Advanced Malignancies
Primary: Progression-free Survival (PFS) — 24.016; 11.072; 16.821 months — p=<0.0001
Phase 1 N=8 Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer · Anlotinib
Primary: the Maximum Tolerated Dose (MTD) — 10 mg
Phase 3 N=207 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
NSCLC (Non-small Cell Lung Cancer)
Primary: Progression-Free Survival (PFS) Based on IRR by Treatment Arm — 11.1; 6.8 Months — p=<0.0001
Phase 3 N=376 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) — 16.6; 8.1 Months — p=<0.001
Phase 3 N=119 Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator — 10.9; 1.4 months — p=<0.001
Phase 2 N=124 LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) by Investigator Assessment — 67.7 Percentage of participants
Phase 3 N=303 A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) by Investigator Assessment — NA; 11.1 months — p=<0.0001
N/A N=449 Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Non-small Cell Lung Cancer
Primary: Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement — 8.69 percentage of participants
N/A N=62 Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Non-Small Cell Lung Cancer
Primary: Prevalence of ALK Fusion — 27 Participants
Phase 2 N=47 A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs): Phase I — 0; 0; 0; 0 participants
Phase 2 N=20 LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.
Non-Small-Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 by Investigator Assessment — 25.0 Percentage of participants
Phase 2 N=103 LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
Non-Small Cell Lung Cancer
Primary: Primary Pharmacokinetics (PK) Parameters of of LDK378 After Daily Oral Dose: AUClast, AUC0-24h, AUCinf — 10100; 3940; 11100 ng*hr/mL
Phase 2 N=140 LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR) to LDK378 Per Investigator Assessment — 40.7 Percentage of participants
Phase 2 N=103 A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
ALK-positive Advanced NSCLC
Primary: Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC) — 26.2 percentage of participants — p=0.0763
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
N/A N=73 Descriptive Observational Study ALK-2016-CPHG
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
Phase 2 N=138 A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Non-Small-Cell Lung Carcinoma
Primary: Recommended Phase 2 Dose (RP2D) of Alectinib
Phase 2 N=364 A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC
Primary: Number of Participants With Cycle 1 Dose-Limiting Toxicities (DLTs) in Phase 1 — 0; 0; 0; 0 Participants
N/A N=572 Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)
Non-Small Cell Lung Cancer
Primary: Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only — 35; 11; 43; 29 Participants
Phase 2 N=53 ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Presence or Absence of a Dose Limiting Toxicity (DLT) of ALT-803 in Combination With Nivolumab — 3; 3; 6; 8 Participants
N/A N=549 Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
ALK-positive NSCLC
Primary: Overall Survival (OS): Based on Treatment Cohort Groups — 1.94; 2.30; 4.56; 2.94 Years
Phase 2 N=31 Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC
Non-small Cell Lung Cancer Stage IV
Primary: Progression Free Survival Rate — 4; 0 Participants
Phase 4 N=71 Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer
Carcinoma · Non-Small-Cell Lung
Primary: Percentage of Participants With Confirmed Overall Objective Response (OR) as Per Independent Central Review (ICR) as Assessed by RECIST v1.1 — 42.3 Percentage of…
Phase 4 N=100 Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India
Advanced Non-Small Cell Lung Cancer
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 94; 89 Participants
Phase 2 N=64 Single Agent Alimta in Poor Performance Status in Non-small Cell Lung Cancer
Lung Cancer
Primary: Objective Response Rate (OR) Where OR=CR+PR: Number of Participants With Responses of Complete Response (CR) and Partial Response (PR) — 3 Participants